At Consilient Health, we market and distribute quality generic pharmaceuticals in Western Europe. With our network of manufacturers and business partners, Consilient strives to make medicines affordable.
Consilient operates a strong and responsive supply chain utilizing state-of-the-art information technology solutions to best manage today’s logistical challenges. Our products are regulated, licensed, and clinically validated to be safe. We ensure the highest quality and reliability, at a competitive price.
We are committed to making generic medicines more accessible to governments and consumers. Our unique business model makes this possible, and allows us to share savings with society-at-large. We are committed to serving society by providing a reliable supply of quality generics.
Reliability is vital to winning and keeping the trust of our partners and customers. We have entered into long-term strategic agreements with a large number of world class manufacturers to be able to guarantee a stable and ongoing supply of our products. We work hard to maintain and extend our network of suppliers and manufacturers in Europe and emerging markets to ensure that our products will be available on demand.
Our objectives cannot be achieved without Consilient being built on a solid foundation. Our multi-national management team has decades of combined experience in the pharmaceutical and health sectors along with an impressive set of personal and professional connections all over Europe. Consilient Health Limited has a small and flexible management team and a network of strong external partners. Our ground-breaking business model allows management to adapt quickly to changing opportunities.
Amongst the many first to market generic launches that we have delivered in our short history, two stand out the most for us – Clopidogrel Tablets, and Nazdol MR Tablets (Gliclazide). Both of these products were first introduced to the UK market by Consilient. There are many more similar launches planned in the coming years.
Message to our customers:
“You can expect a premium product and reliable service, at competitive prices.”
Facts and Figures:
  • Formed in 2005. Privately owned.
  • First product launch in the UK – Lamotrigine Tablets (July 2005)
  • Over 25 products launched since August 2005
  • Strong focus on developing and launching patent expiring generics on Day 1 (11 launched to date on time), & niche products
  • Products promoted by experienced National and Regional Channel Managers directly to pharmacies across the UK.